181 related articles for article (PubMed ID: 33414758)
1. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse.
Kaplan J; Miller T; Baker M; Due B; Zhao E
Front Neurol; 2020; 11():598496. PubMed ID: 33414758
[No Abstract] [Full Text] [Related]
2. Repository corticotropin injection improves quality metrics in an observational study of multiple sclerosis relapse.
Kaplan J; Miller T; Baker M; Due B; Zhao E
Neurodegener Dis Manag; 2021 Dec; 11(6):469-476. PubMed ID: 34860120
[TBL] [Abstract][Full Text] [Related]
3. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids.
Wynn D; Goldstick L; Bauer W; Zhao E; Tarau E; Cohen JA; Robertson D; Miller A
CNS Neurosci Ther; 2022 Mar; 28(3):364-371. PubMed ID: 34984839
[TBL] [Abstract][Full Text] [Related]
4. Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis.
Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ
Neurol Ther; 2021 Jun; 10(1):149-167. PubMed ID: 33170434
[TBL] [Abstract][Full Text] [Related]
5. Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis.
Mirsaeidi M; Baughman RP; Sahoo D; Tarau E
Pulm Ther; 2023 Jun; 9(2):237-253. PubMed ID: 37072607
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
Philbin M; Niewoehner J; Wan GJ
Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550
[TBL] [Abstract][Full Text] [Related]
8. Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence.
Wan GJ; Niewoehner J; Hayes K
Clinicoecon Outcomes Res; 2023; 15():499-512. PubMed ID: 37397803
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis.
Hunter SF; Bindra J; Chopra I; Niewoehner J; Panaccio MP; Wan GJ
Clinicoecon Outcomes Res; 2021; 13():883-892. PubMed ID: 34675568
[TBL] [Abstract][Full Text] [Related]
10. Repository Corticotropin Injection (Acthar
Wirta D; McLaurin E; Ousler G; Liu J; Kacmaz RO; Grieco J
Ophthalmol Ther; 2021 Dec; 10(4):1077-1092. PubMed ID: 34669183
[TBL] [Abstract][Full Text] [Related]
11. Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population.
Nazareth T; Datar M; Yu TC
Neurol Ther; 2019 Dec; 8(2):383-395. PubMed ID: 31564036
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
13. Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid Arthritis.
Fleischmann R; Hayes K; Ahn SW; Wan GJ; Panaccio MP; Karlsson D; Furst DE
Rheumatol Ther; 2022 Apr; 9(2):435-446. PubMed ID: 34919213
[TBL] [Abstract][Full Text] [Related]
14. Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease.
Toyos M; Toyos R; Jodoin B; Bunch R
Ophthalmol Ther; 2022 Jun; 11(3):1231-1240. PubMed ID: 35460497
[TBL] [Abstract][Full Text] [Related]
15. Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis.
Busch H; Wan GJ; Niewoehner J; Houston P; Su Y; Clinton C; Panaccio MP
Drugs Context; 2022; 11():. PubMed ID: 35382109
[TBL] [Abstract][Full Text] [Related]
16. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
[TBL] [Abstract][Full Text] [Related]
17. H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes.
Kutz C
Ther Adv Chronic Dis; 2016 Jul; 7(4):190-7. PubMed ID: 27433309
[TBL] [Abstract][Full Text] [Related]
18. Follow-up results of myositis patients treated with H. P. Acthar gel.
Saygin D; Oddis CV; Marder G; Moghadam-Kia S; Nandkumar P; Neiman N; Dzanko S; Koontz D; Aggarwal R
Rheumatology (Oxford); 2020 Oct; 59(10):2976-2981. PubMed ID: 32160301
[TBL] [Abstract][Full Text] [Related]
19. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Askanase AD; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2020 Dec; 7(4):893-908. PubMed ID: 32996096
[TBL] [Abstract][Full Text] [Related]
20. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]